Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline
Kameshwar Prasad, Reed Siemieniuk, Qiukui Hao, Gordon Guyatt, Martin O'Donnell, Lyubov Lytvyn, Anja Fog Heen, Thomas Agoritsas, Per Olav Vandvik, Sankar Prasad Gorthi, Loraine Fisch, Mirza Jusufovic, Jennifer Muller, Brenda Booth, Eleanor Horton, Auxiliadora Fraiz, Jillian Siemieniuk, Awah Cletus Fobuzi, Neelima Katragunta, Bram Rochwerg
BMJ: British Medical Journal 2018 December 18, 363: k5130
30563885
WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG.
Full Text Links
Find Full Text Links for this Article
You are not logged in. Sign Up or Log In to join the discussion.